Bristol Myers Squibb (CELG-RI) Non-Current Debt (2009 - 2026)
Bristol Myers Squibb (CELG-RI) posted quarterly Non-Current Debt of $42.9 billion for Q2 2026, down 12.43% year-over-year from $48.9 billion in Q2 2025, and down 2.9% quarter-over-quarter from $44.1 billion in Q1 2026.
Bristol Myers Squibb (CELG-RI) Non-Current Debt (2009 - 2026) Analysis & Trends
Bristol Myers Squibb (CELG-RI) has reported Non-Current Debt for 18 consecutive years, with $42.9 billion the latest figure, recorded in Q2 2026.
- In Q2 2026, Non-Current Debt fell 12.43% year-over-year to $42.9 billion; the TTM figure through Jun 2026 stood at $42.9 billion (down 12.43% YoY), while the FY2025 annual figure was $44.8 billion, down 9.31% from the prior year.
- Non-Current Debt declined to $42.9 billion in Q2 2026 per CELG-RI's latest filing, from $44.1 billion in the prior quarter.
- Across five years, Non-Current Debt topped out at $52.4 billion in Q1 2024 and bottomed at $37.0 billion in Q3 2023.
- Historically, Non-Current Debt has averaged $44.3 billion across 5 years, with a median of $44.4 billion in 2022.
- Annual changes were most pronounced in 2023 — Non-Current Debt decreased 16.57% — and 2024, when it jumped 40.26%.
- Bristol Myers Squibb's Non-Current Debt stood at $39.0 billion in 2022, then rose by 1.47% to $39.5 billion in 2023, then grew by 25.06% to $49.4 billion in 2024, then declined by 9.31% to $44.8 billion in 2025, then retreated by 4.39% to $42.9 billion in 2026.
- Business Quant data shows CELG-RI's Non-Current Debt at $42.9 billion in Q2 2026, $44.1 billion in Q1 2026, and $44.8 billion in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Debt (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 654.04 Bn | 633.28 Bn | 17.26 Bn | 37.34 Bn |
| 2 | AbbVie | 470.61 Bn | 464.04 Bn | 12.70 Bn | 62.48 Bn |
| 3 | Merck | 379.00 Bn | 371.86 Bn | 12.21 Bn | 51.08 Bn |
| 4 | Novartis Ag | 303.30 Bn | 295.61 Bn | 11.24 Bn | - |
| 5 | Astrazeneca | 258.47 Bn | 253.57 Bn | 12.86 Bn | 23.68 Bn |
| 6 | Amgen | 237.78 Bn | 223.79 Bn | 7.24 Bn | 57.30 Bn |
| 7 | Gilead Sciences | 183.75 Bn | 180.57 Bn | 6.22 Bn | 26.25 Bn |
| 8 | Pfizer | 160.91 Bn | 149.21 Bn | 10.94 Bn | 60.50 Bn |
| 9 | Gsk | 106.07 Bn | 101.90 Bn | 8.24 Bn | -18.71 Bn |
| 10 | Bristol Myers Squibb | 208.28 Mn | -10.86 Bn | 9.25 Bn | 42.86 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 42.86 Bn |
| Mar 31, 2026 | 44.14 Bn |
| Dec 31, 2025 | 42.85 Bn |
| Sep 30, 2025 | 44.47 Bn |
| Jun 30, 2025 | 48.95 Bn |
| Mar 31, 2025 | 46.16 Bn |
| Dec 31, 2024 | 49.43 Bn |
| Sep 30, 2024 | 48.67 Bn |
| Jun 30, 2024 | 51.95 Bn |
| Mar 31, 2024 | 49.49 Bn |
| Dec 31, 2023 | 39.53 Bn |
| Sep 30, 2023 | 32.14 Bn |
| Jun 30, 2023 | 34.66 Bn |
| Mar 31, 2023 | 35.08 Bn |
| Dec 31, 2022 | 38.95 Bn |
| Sep 30, 2022 | 38.87 Bn |
| Jun 30, 2022 | 37.11 Bn |
| Mar 31, 2022 | 44.75 Bn |
| Dec 31, 2021 | 39.61 Bn |
| Sep 30, 2021 | 44.45 Bn |